{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:45:41Z","timestamp":1785746741162,"version":"3.56.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>Current European expert consensus definitions for esophagogastric oligometastatic disease (OMD) primarily relate to adenocarcinoma. Oligometastatic esophageal squamous cell carcinoma (OMESQ) may require a distinct definition and treatment strategy. This systematic review and meta-analysis aimed to identify applied OMESQ definitions and assess the impact of local treatment on overall survival (OS). A systematic search of PubMed, Embase, CENTRAL, and ClinicalTrials.gov was conducted (February 2026). Studies or protocols were eligible if they reported an OMESQ definition or outcomes of local treatment in patients with limited metastatic ESCC. The primary outcomes were the maximum number of involved organs and metastases defined as OMD. Agreement across studies was scored as absent\/poor (&amp;lt; 50%), fair (50%\u201375%), or strong (\u2265 75%). A meta-analysis of OS after local treatment (+\/\u2212 systemic therapy) versus systemic therapy alone was conducted through a random-effects pooled analysis of hazard ratios (HRs). Of the 3844 screened articles, 27 studies (23 retrospective, 4 prospective [one randomized]) and 7 protocols were included. Agreement was observed for defining synchronous OMESQ as disease in one organ with \u22643 metastases and metachronous OMESQ as disease in one organ with \u22642 metastases. Across 10 studies, meta-analysis showed that local treatment (+\/\u2212 systemic therapy) was associated with improved OS compared with systemic therapy alone (pooled HR 0.61, 95% confidence interval: 0.52\u20130.72; I2\u2009=\u200950.7%). Current literature and trial protocols considers OMESQ as \u22643 synchronous or\u2009\u2264\u20092 metachronous metastases in 1 organ. Local treatment is associated with improved OS compared with systemic therapy alone.<\/jats:p>","DOI":"10.1093\/dote\/doag078","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:41:47Z","timestamp":1784029307000},"source":"Crossref","is-referenced-by-count":0,"title":["Oligometastatic esophageal squamous cell carcinoma: a systematic review of current definitions and meta-analysis of local therapy outcomes"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5967-0610","authenticated-orcid":false,"given":"Motoo","family":"Nomura","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Kyoto University Hospital , Kyoto ,","place":["Japan"]},{"name":"Department of Head and Neck Oncology and Innovative Treatment, Graduate School of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4985-2590","authenticated-orcid":false,"given":"Sebastiaan F C","family":"Bronzwaer","sequence":"additional","affiliation":[{"name":"Department of Surgery, UMC - University Medical Center Utrecht , Utrecht ,","place":["Netherlands"]},{"name":"Department of Radiation Oncology, Amsterdam UMC - Vrije University Medical Centre (VUmc) , Amsterdam ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiuri E","family":"Kroese","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-8388","authenticated-orcid":false,"given":"Peter S N","family":"van Rossum","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Amsterdam UMC - Vrije University Medical Centre (VUmc) , Amsterdam ,","place":["Netherlands"]},{"name":"Cancer Center Amsterdam, Cancer Treatment and Quality of Life , Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle P","family":"Ruurda","sequence":"additional","affiliation":[{"name":"Department of Surgery, UMC - University Medical Center Utrecht , Utrecht ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-261X","authenticated-orcid":false,"given":"Richard","family":"van Hillegersberg","sequence":"additional","affiliation":[{"name":"Department of Surgery, UMC - University Medical Center Utrecht , Utrecht ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-5072","authenticated-orcid":false,"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Kanagawa Cancer Center , Yokohama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-3819","authenticated-orcid":false,"given":"Mitsuro","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hamai","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsubosa","sequence":"additional","affiliation":[{"name":"Division of Esophageal Surgery, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saitama Prefectural Cancer Center , Ina ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Furuta","sequence":"additional","affiliation":[{"name":"Gastroenterology, Kanagawa Cancer Center , Yokohama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1590-0250","authenticated-orcid":false,"given":"Katsuyuki","family":"Sakanaka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine and Faculty of Medicine, Kyoto University , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-2755","authenticated-orcid":false,"given":"Satoru","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-7504","authenticated-orcid":false,"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W M","family":"Laarhoven","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Cancer Treatment and Quality of Life , Amsterdam ,","place":["the Netherlands"]},{"name":"Department of Medical Oncology, Amsterdam University Medical Center, University of Amsterdam , Amsterdam ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3947-0128","authenticated-orcid":false,"given":"Hiroya","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hamamatsu University School of Medicine , Hamamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026080304002384600_ref1","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1097\/CM9.0000000000003420","article-title":"Global esophageal cancer epidemiology in 2022 and predictions for 2050: a comprehensive analysis and projections based on GLOBOCAN data","volume":"137","author":"Qi","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2026080304002384600_ref2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10388-025-01141-8","article-title":"Comprehensive registry of esophageal cancer in Japan, 2016","volume":"22","author":"Kimura","year":"2025","journal-title":"Esophagus"},{"key":"2026080304002384600_ref3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet."},{"key":"2026080304002384600_ref4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2026080304002384600_ref5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026080304002384600_ref6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"2026080304002384600_ref7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026080304002384600_ref8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.radonc.2022.06.012","article-title":"Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study","volume":"173","author":"Kroese","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026080304002384600_ref9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026080304002384600_ref10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","article-title":"A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III Esophageal squamous cell carcinoma (JCOG0909 study)","volume":"114","author":"Takeuchi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080304002384600_ref11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026080304002384600_ref12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"2026080304002384600_ref13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese classification of Esophageal cancer, 12th edition: part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus."},{"key":"2026080304002384600_ref14","first-page":"185","volume-title":"AJCC Cancer Staging Manual","author":"Rice","year":"2017","edition":"8"},{"key":"2026080304002384600_ref15","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1245\/s10434-022-12996-x","article-title":"Safety and feasibility of robot-assisted minimally invasive esophagectomy (RAMIE) with three-field lymphadenectomy and neoadjuvant chemoradiotherapy in patients with Resectable Esophageal cancer and cervical lymph node metastasis","volume":"30","author":"Horst","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2026080304002384600_ref16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2019.07.010","article-title":"Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting","volume":"3","author":"Aluwini","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2026080304002384600_ref17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2026080304002384600_ref18","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ."},{"key":"2026080304002384600_ref19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026080304002384600_ref20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00268-012-1830-7","article-title":"Pattern of postoperative recurrence and hepatic and\/or pulmonary resection for liver and\/or lung metastases from esophageal carcinoma","volume":"37","author":"Ichida","year":"2013","journal-title":"World J Surg"},{"key":"2026080304002384600_ref21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/dote.12034","article-title":"Radiofrequency ablation for pulmonary metastases from esophageal squamous cell carcinoma","volume":"27","author":"Baba","year":"2014","journal-title":"Dis Esophagus"},{"key":"2026080304002384600_ref22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00595-014-1036-8","article-title":"Surgical outcomes of pulmonary metastases from esophageal carcinoma diagnosed by both pathological and clinical criteria","volume":"45","author":"Kozu","year":"2015","journal-title":"Surg Today"},{"key":"2026080304002384600_ref23","first-page":"418","article-title":"Surgery for malignant pulmonary nodules in patients with a history of oesophageal cancer","volume":"24","author":"Kanzaki","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026080304002384600_ref24","first-page":"S334","article-title":"Liver metastases from Esophageal carcinoma","volume":"20","author":"Kostov","year":"2018","journal-title":"HPB"},{"key":"2026080304002384600_ref25","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1111\/ans.13810","article-title":"Hepatic resection for post-operative solitary liver metastasis from oesophageal squamous cell carcinoma","volume":"88","author":"Liu","year":"2018","journal-title":"ANZ J Surg"},{"key":"2026080304002384600_ref26","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.21037\/jtd.2019.03.10","article-title":"Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases","volume":"11","author":"Chen","year":"2019","journal-title":"J Thorac Dis"},{"key":"2026080304002384600_ref27","doi-asserted-by":"crossref","first-page":"e611","DOI":"10.1016\/j.ijrobp.2020.07.1857","article-title":"Efficacy of radiotherapy In oligometastatic Esophageal squamous cell cancer patients: new evidence from a retrospective study","volume":"108","author":"Li","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080304002384600_ref28","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2021.09.033","article-title":"Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses","volume":"164","author":"Shi","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026080304002384600_ref29","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00595-020-02173-6","article-title":"Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma","volume":"51","author":"Morinaga","year":"2021","journal-title":"Surg Today"},{"key":"2026080304002384600_ref30","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.21037\/tcr.2020.03.47","article-title":"Long term results of different radiotherapy techniques and fractions for esophageal squamous cell carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Transl Cancer Res"},{"key":"2026080304002384600_ref31","doi-asserted-by":"crossref","first-page":"E2244619","DOI":"10.1001\/jamanetworkopen.2022.44619","article-title":"Evaluation of concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic Esophageal squamous cell carcinoma","volume":"5","author":"Shi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026080304002384600_ref32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5090\/jcs.23.050","article-title":"The prognostic value of oligo-recurrence following esophagectomy for Esophageal cancer","volume":"56","author":"Kang","year":"2023","journal-title":"J Chest Surg"},{"key":"2026080304002384600_ref33","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.annonc.2024.05.326","article-title":"Survival outcome and safety of different treatment models in patients with oligometastatic esophageal cancer with only distant lymph node metastasis","volume":"35","author":"Qiu","year":"2024","journal-title":"Ann Oncol"},{"key":"2026080304002384600_ref34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cpt.2025.02.003","article-title":"Efficacy of local consolidative radiotherapy with first-line chemoimmunotherapy in synchronous oligometastatic esophageal squamous cell carcinoma","volume":"3","author":"Wang","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"2026080304002384600_ref35","doi-asserted-by":"crossref","first-page":"110289","DOI":"10.1016\/j.ejso.2025.110289","article-title":"Pretracheal (No.106pre) lymph node metastasis in esophageal carcinoma: a sign of widespread disease progression, but potentially treatable as oligometastatic disease through neoadjuvant chemotherapy followed by surgery - a multicenter cohort study","volume":"51","author":"Igaue","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"2026080304002384600_ref36","first-page":"1","article-title":"Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer","volume":"16","author":"Duan","year":"2025","journal-title":"Future Oncol"},{"key":"2026080304002384600_ref37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10388-025-01126-7","article-title":"Treatment strategies and long-term outcomes for patients with oligometastasis in esophageal squamous cell carcinoma after radical esophagectomy","volume":"22","author":"Ishida","year":"2025","journal-title":"Esophagus."},{"key":"2026080304002384600_ref38","first-page":"e70248","article-title":"Stereotactic body radiation therapy for oligometastatic recurrent Esophageal squamous cell carcinoma: a retrospective cohort study from a single tertiary Center","volume":"8","author":"Katano","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"2026080304002384600_ref39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00066-024-02347-y","article-title":"Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma","volume":"201","author":"Lv","year":"2025","journal-title":"Strahlenther Onkol"},{"key":"2026080304002384600_ref40","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.3390\/cancers17213407","article-title":"Treatment outcomes and significance of multimodal treatment in Esophageal squamous cell carcinoma with synchronous Oligometastasis","volume":"17","author":"Ohsawa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026080304002384600_ref41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00262-025-04228-4","article-title":"Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study","volume":"74","author":"Liu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026080304002384600_ref42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1245\/s10434-024-16196-7","article-title":"Safety and efficacy of conversion therapy after systemic chemotherapy in advanced Esophageal cancer with distant metastases: a Multicenter retrospective observational study","volume":"32","author":"Tsuji","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026080304002384600_ref43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","article-title":"Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic Esophageal squamous cell carcinoma","volume":"108","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080304002384600_ref44","doi-asserted-by":"crossref","first-page":"S902","DOI":"10.1016\/j.annonc.2024.08.1518","article-title":"Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): a single-arm, open-label, phase II trial","volume":"35","author":"Huang","year":"2024","journal-title":"Ann Oncol"},{"key":"2026080304002384600_ref45","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1038\/s41467-024-51105-2","article-title":"Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"2026080304002384600_ref46","doi-asserted-by":"crossref","first-page":"114062","DOI":"10.1016\/j.ejca.2024.114062","article-title":"European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)","volume":"204","author":"Kroese","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026080304002384600_ref47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/aoe-2025-1-42","article-title":"Definition and treatment strategies for oligometastatic esophageal squamous cell carcinoma (OMESQ): a study protocol for global multidisciplinary consensus using the modified Delphi method","volume":"8","author":"Nomura","year":"2025","journal-title":"Ann Esophagus"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/4\/doag078\/70461321\/doag078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/dote\/article-pdf\/39\/4\/doag078\/70461321\/doag078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:00:31Z","timestamp":1785744031000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doag078\/8749462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doag078","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"doag078"}}